News
GMAB
35.36
+0.11%
0.04
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
NASDAQ · 2d ago
Bank of America Securities Sticks to Their Buy Rating for Genmab A/S (0MGB)
TipRanks · 3d ago
Genmab Grants New Employee Restricted Stock Units and Warrants
TipRanks · 4d ago
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 4d ago
Top 20 Nasdaq-100 names powering the NDX’s 2026 record run
Seeking Alpha · 6d ago
Weekly Report: what happened at GMAB last week (0914-0918)?
Weekly Report · 09/21 09:11
Analysts Are Bullish on These Healthcare Stocks: Genmab (GMAB), Medicus Pharma Ltd (MDCX)
TipRanks · 09/14 11:30
Genmab Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Dow Jones · 09/14 10:25
HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target
Benzinga · 09/14 10:14
Weekly Report: what happened at GMAB last week (0907-0911)?
Weekly Report · 09/14 09:11
Genmab Updates Articles of Association, Preserves Broad Capital-Raising Powers
TipRanks · 09/09 15:17
Genmab Raises Share Capital via Employee Warrant Exercise
TipRanks · 09/09 10:50
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Barchart · 09/08 13:44
Genmab Calls October Extraordinary General Meeting to Address Board Remuneration and Shareholder Outreach
TipRanks · 09/08 12:18
Genmab A/S (0MGB) Receives a Buy from Barclays
TipRanks · 09/08 06:36
Notice to Convene an Extraordinary General Meeting of Genmab A/S
Barchart · 09/08 05:00
Genmab A/S (0MGB) Gets a Buy from Bank of America Securities
TipRanks · 09/07 12:05
Weekly Report: what happened at GMAB last week (0831-0904)?
Weekly Report · 09/07 09:11
Genmab price target raised to DKK 2,500 from DKK 2,250 at Deutsche Bank
TipRanks · 09/01 16:35
3 Best Stocks With 140%+ Upside to Buy in September, According to Analysts
TipRanks · 09/01 16:03
More
Webull provides a variety of real-time GMAB stock news. You can receive the latest news about Genmab through multiple platforms. This information may help you make smarter investment decisions.
About GMAB
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.